市場調查報告書

血管運動神經症狀(發熱/發汗)- 流行病學預測 2030年

Vasomotor symptoms (Hot flashes/Night sweats) - Epidemiology Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 928281
出版日期 內容資訊 英文 75 Pages
商品交期: 最快1-2個工作天內
價格
血管運動神經症狀(發熱/發汗)- 流行病學預測 2030年 Vasomotor symptoms (Hot flashes/Night sweats) - Epidemiology Forecast - 2030
出版日期: 2020年03月01日內容資訊: 英文 75 Pages
簡介

主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的血管運動神經症狀(發熱/發汗)的2017年的患病數估計為4,109萬6,968人。

本報告提供主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的血管運動神經症狀(發熱/發汗)市場相關調查,疾病概要,及主要7個國家的市場趨勢,流行病學的預測,各重症度的患病數的變化與預測等資訊總括性彙整。

目錄

第1章 重要的洞察

第2章 血管運動神經症狀(發熱/發汗):市場概要

  • 市場佔有率(預測值)
  • 市場佔有率(成果值)

第3章 摘要整理

第4章 相關組織

第5章 流行病學與調查手法

第6章 停經後的血管運動神經症狀:疾病背景和概要

  • 簡介
  • 血管運動神經症狀
  • 徵兆與症狀
  • 病理生理學
  • 危險因素
  • 影響
  • 早發性閉經
  • 乳癌治療伴隨的更年期障礙

第7章 流行病學和患者數

  • 主要調查結果

第8章 主要7個國家的血管運動神經症狀的總患病數

第9章 停經後血管運動神經症狀的流行病學:各國

  • 美國
    • 假設和根據
    • 總患病數
    • 患病數:各重症度
  • 歐洲5個國家
    • 德國
      • 假設和根據
      • 總患病數
      • 患病數:各重症度
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第10章 關鍵意見領袖的意見

第11章 附錄

  • 報告方法

第12章 DelveInsight的服務內容

第13章 免責聲明

第14章 關於DelveInsight

目錄
Product Code: DIEI0876

DelveInsight's 'Vasomotor symptoms (Hot flashes/Night sweats)- Epidemiology Forecast-2030' report delivers an in-depth understanding of the Vasomotor symptoms including Hot flashes or night sweats, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom) and Japan.

Vasomotor symptoms (Hot flashes/Night sweats) Disease Understanding

Vasomotor symptoms are one of the major symptoms of menopause that principally include hot flashes (HF) and night sweats (NS) and occurs in the majority of women across the globe. A woman with VMS experiences abundant heat accompanied by sweating and flushing, especially around the head, neck, chest, and upper back region. These are the menopausal symptoms for which women seek treatment during menopause most often. VMS results from temperature dysfunction that occurs due to changes in gonadal hormones. Normally, core body temperature (CBT) remains within a specific range, oscillating with daily circadian rhythms.

Menopause is characterized by physiologic and psychosocial changes in a woman's life. VMS, and the sleep and mood disturbances that often result from these, can have a significant negative impact on the overall quality of life (QOL) for a substantial number of women. The impact of VMS has gained in importance as the lifespan of women has increased throughout the world since women can expect to spend a significant portion of their lives after menopause. Maintenance of functional ability and a good QOL is of utmost importance. Given the prevalence and duration of VMS among midlife women, it is critical to understand the underlying biology of this symptom, the extent to which VMS may impair QOL, and whether VMS may serve as a marker for other important health conditions. VMS experienced in up to 80% of menopausal women, prevalence depends on region. The vasomotor symptoms may range in severity from discomfort to debilitation. More than half of the women with VMS experience "moderate to severe" symptoms.

Vasomotor symptoms (Hot flashes/Night sweats) Epidemiology

The Vasomotor symptoms epidemiology division provide insights about the historical and current patient pool of Hot flashes/Night sweats and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The total diagnosed prevalent cases of vasomotor symptoms (Hot flashes/Night sweats) patients were found to be more in postmenopausal women aged 40-65 years in 7MM during the study period, i.e. 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted vasomotor symptoms epidemiology segmented as the prevalence of Vasomotor symptoms, Prevalent Cases of Hot Flashes associated with Post Menopause, Severity-specific cases of Hot flashes (Mild, Moderate and Severe) in post-menopause and Diagnosed and Treatable Cases of Vasomotor symptoms.

The report includes the prevalent scenario of Vasomotor symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Country Wise- Vasomotor symptoms (Hot flashes/Night sweats) Epidemiology

The epidemiology segment also provides the Vasomotor symptoms (Hot flashes/Night sweats) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The total prevalent population of Vasomotor Symptoms Associated with post-menopause in 7MM countries was found to be 41,096,968 in 2017.

  • As per the estimates, United States has the highest prevalent population of Hot Flashes associated with Post Menopause.
  • Among the European countries, Germany had the highest prevalent population of Hot Flashes and Spain had the lowest prevalent population in 2017.

Scope of the Report

  • The Vasomotor symptoms (Hot flashes/Night sweats) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Vasomotor symptoms (Hot flashes/Night sweats) Epidemiology Report and Model provide an overview of the risk factors and global trends of Vasomotor symptoms (Hot flashes/Night sweats) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Vasomotor symptoms (Hot flashes/Night sweats) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Vasomotor symptoms
  • The report provides the segmentation of the Vasomotor symptoms (Hot flashes/Night sweats) epidemiology by -specific Prevalent Cases of Vasomotor symptoms (Hot flashes/Night sweats) in 7MM
  • The report provides the segmentation of the Vasomotor symptoms (Hot flashes/Night sweats) epidemiology by Gender-specific Cases of Vasomotor symptoms (Hot flashes/Night sweats) in 7MM

Report Highlights

  • 11-Year Forecast of Vasomotor symptoms (Hot flashes/Night sweats) epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of Vasomotor symptoms (Hot flashes/Night sweats) in post menopause
  • Prevalent Cases according to segmentation: Severity-specific Prevalence of hot flashes
  • Diagnosed cases of Vasomotor symptoms

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Vasomotor symptoms?
  • What are the key findings pertaining to the Vasomotor symptoms (Hot flashes/Night sweats) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Vasomotor symptoms (Hot flashes/Night sweats) across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Vasomotor symptoms?
  • What are the currently available treatments of Vasomotor symptoms?

Reasons to buy

The Vasomotor symptoms (Hot flashes/Night sweats) Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Vasomotor symptoms (Hot flashes/Night sweats) market
  • Quantify patient populations in the global Vasomotor symptoms (Hot flashes/Night sweats) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Vasomotor symptoms (Hot flashes/Night sweats) therapeutics in each of the markets covered
  • Understand the magnitude of Vasomotor symptoms (Hot flashes/Night sweats) population by its severity
  • The Vasomotor symptoms (Hot flashes/Night sweats) epidemiology report and model were written and developed by Masters and PhD level epidemiologists
  • The Vasomotor symptoms (Hot flashes/Night sweats) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

With the aging of the worldwide population in the coming decades, it is estimated that 1.2 billion women worldwide will be menopausal or postmenopausal by the year 2030. Among them, Vasomotor symptoms, Hot flashes are extremely common affecting approximately 85% of menopausal women. Nearly 55% of women experience Hot flashes as they enter the transition phase toward menopause. In the post-menopause, Hot flashes becoming most troublesome with increasing severity.

The International Menopause Society (IMS) Council of Affiliated Menopause Societies (CAMS) have collaborated in studies to compare the prevalence of HFs in different climates, continents and at different altitudes.

Severity-specific prevalence of Hot Flashes and Sweat nights: A large number of women reported moderate to severe vasomotor symptoms. Perimenopausal women showed more severe symptoms as compared to women in the post-menopause stage. The frequency and severity of Night Sweats were lower than that of Hot Flashes, yet it may greatly impact women's health through the loss of sleep. Additionally, one's lifestyle and environmental factors have been reported to either worsen the symptoms or make them better. Hot flashes were reported to be worse in the evening for approximately one-third of postmenopausal women.

The prevalence of hot flashes in Japan is lower than in western countries. The remarkably lower prevalence of menopausal symptoms such as Hot Flashes among Japanese women compared with their counterparts in the western countries challenged the conventional view of menopause as a biologically uniform experience.

Table of Contents

1. Key Insights

2. Vasomotor Symptoms (Hot Flashes/Night Sweats): Epidemiology Overview at a Glance

  • 2.1. Total Patient Share (%) Distribution of Vasomotor Symptoms (Hot Flashes/Night Sweats) in 2017
  • 2.2. Total Patient Share (%) Distribution of Vasomotor Symptoms (Hot Flashes/Night Sweats) in 2030

3. Executive summary

4. Organizations

5. Epidemiology Methodology

6. Vasomotor Symptoms (VMS) associated with menopause: Disease Background and Overview

  • 6.1. Introduction
  • 6.2. Vasomotor Symptoms (Hot Flashes/Night Sweats)
  • 6.3. Signs and Symptoms of VMS
  • 6.4. Pathophysiology of VMS
  • 6.5. Risk factors for VMS
  • 6.6. Effects of VMS
  • 6.7. Premature (early) Menopause
  • 6.8. Menopause Associated with Breast Cancer Treatment

7. Epidemiology and Patient Population

  • 7.1. Key Findings

8. Total Prevalent cases of Vasomotor Symptoms (Hot Flashes/Night Sweats) in Post-menopause in 7MM

9. Country Wise-Epidemiology of Hot Flashes Associated with Post-menopause

  • 9.1. United States
    • 9.1.1. Assumptions and Rationale
    • 9.1.2. Total Prevalent Population of Vasomotor Symptoms (Hot Flashes/Night Sweats) Associated with Post-menopause in the United States
    • 9.1.3. Severity-Specific cases of Hot Flashes in Post-menopause in the United States
  • 9.2. EU5 Countries
  • 9.3. Germany
    • 9.3.1. Assumptions and Rationale
    • 9.3.2. Total Prevalent Population of Vasomotor Symptoms (Hot Flashes/Night Sweats) Associated with Post-menopause in Germany
    • 9.3.3. Severity-Specific cases of Hot Flashes in Post-menopause in the Post-menopause in Germany
  • 9.4. France
    • 9.4.1. Assumptions and Rationale
    • 9.4.2. Total Prevalent Population of Vasomotor Symptoms (Hot Flashes/Night Sweats) Associated with Post-menopause in France
    • 9.4.3. Severity-Specific cases of Hot Flashes in Post-menopause in the with Post-menopause in France
  • 9.5. Italy
    • 9.5.1. Assumptions and Rationale
    • 9.5.2. Total Prevalent Population of Vasomotor Symptoms (Hot Flashes/Night Sweats) Associated with Post-menopause in Italy
    • 9.5.3. Severity-Specific cases of Hot Flashes in Post-menopause in the Post-menopause in Italy
  • 9.6. Spain
    • 9.6.1. Assumptions and Rationale
    • 9.6.2. Total Prevalent Population of Vasomotor Symptoms (Hot Flashes/Night Sweats) Associated with Post-menopause in Spain
    • 9.6.3. Severity-Specific cases of Hot Flashes in Post-menopause in the Post-menopause in Spain
  • 9.7. The United Kingdom
    • 9.7.1. Assumptions and Rationale
    • 9.7.2. Total Prevalent Population of Vasomotor Symptoms (Hot Flashes/Night Sweats) Associated with Post-menopause in the UK
    • 9.7.3. Severity-Specific cases of Hot Flashes in Post-menopause in the Post-menopause in the UK
  • 9.8. Japan
    • 9.8.1. Assumptions and Rationale
    • 9.8.2. Total Prevalent Population of Vasomotor Symptoms (Hot Flashes/Night Sweats) Associated with Post-menopause in Japan
    • 9.8.3. Severity-Specific cases of Hot Flashes in Post-menopause in the Post-menopause in Japan

10. KOL Views

11. Appendix

  • 11.1. Report Methodology

12. DelveInsight Capabilities

13. Disclaimer

14. About DelveInsight

List of Tables

  • Table 1 Conditions that may cause or mimic vasomotor events and that can be distinguished from menopausal symptoms by history, examination, and investigations
  • Table 2 Total Prevalent cases of Vasomotor Symptoms (Hot Flashes) in Post-menopause in 7MM (2017-2030)
  • Table 3 Total Prevalent Population of Hot Flashes Associated with Post-menopause in the United States (2017-2030)
  • Table 4 Severity Specific Prevalence of Hot Flashes Associated with Post menopause in the United States (2017-2030)
  • Table 5 Total Prevalent Population of Hot Flashes associated with Post Menopause in Germany (2017-2030)
  • Table 6 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in Germany (2017-2030)
  • Table 7 Total Prevalent Population of Hot Flashes Associated with Post-menopause in France (2016-2027)
  • Table 8 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in France (2017-2030)
  • Table 9 Total Prevalent Population of Hot Flashes Associated with Post-menopause in Italy (2016-2027)
  • Table 10 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in Italy (2017-2030)
  • Table 11 Total Prevalent Population of Hot Flashes Associated with Post-menopause in Spain (2017-2030)
  • Table 12 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in Spain (2017-2030)
  • Table 13 Total Prevalent Population of Hot Flashes Associated with Post-menopause in the UK (2017-2030)
  • Table 14 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in the UK (2017-2030)
  • Table 15 Total Prevalent Population of Hot Flashes Associated with Post-menopause in Japan (2017-2030)
  • Table 16 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in Japan (2017-2030)

List of Figures

  • Figure 1 Epidemiology and Market Methodology
  • Figure 2 Stages of menopause
  • Figure 3 Vasomotor Symptoms
  • Figure 4 The 3 major components involved in the thermoregulatory function.
  • Figure 5 Relationship between estrogen and a woman's reproductive phases and the occurrence of hot flashes.
  • Figure 6 Maintenance of core body temperature (CBT) is critical to organ integrity and optimal function.
  • Figure 7 Relationship between estrogen and a woman's reproductive phases and the occurrence of hot flashes.
  • Figure 8 Risk factors for VMS
  • Figure 9 Effects of VMS
  • Figure 10 Impact of VMS on QOL
  • Figure 11 Breast Cancer therapies causing Menopause
  • Figure 12 Total Prevalent cases of Vasomotor Symptoms (Hot Flashes) in Post-menopause in 7MM (2017-2030)
  • Figure 13 Prevalence of Hot Flashes Associated with Post menopause in the United States (2017-2030)
  • Figure 14 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in the US (2017-2030)
  • Figure 15 Prevalence of Hot Flashes associated with Post Menopause in Germany (2017-2030)
  • Figure 16 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in Germany (2017-2030)
  • Figure 17 Prevalence of Hot Flashes Associated with Post-menopause in France (2017-2030)
  • Figure 18 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in France (2017-2030)
  • Figure 19 Prevalence of Hot Flashes Associated with Post-menopause in Italy (2017-2030)
  • Figure 20 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in Italy (2017-2030)
  • Figure 21 Prevalence of Hot Flashes Associated with Post-menopause in Spain (2017-2030)
  • Figure 22 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in Spain (2017-2030)
  • Figure 23 Prevalence of Hot Flashes Associated with Post-menopause in the UK (2017-2030)
  • Figure 24 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in the UK (2017-2030)
  • Figure 25 Prevalence of Hot Flashes Associated with Post-menopause in Japan (2017-2030)
  • Figure 26 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in Japan (2017-2030)
  • Figure 27 Non-hormonal pharmacological treatments for vasomotor symptoms
  • Figure 28 Unmet Needs of Hot Flashes